Mycrodose Therapeutics Successfully Delivers Both Macro and Microdose Levels of Psilocin Using Core Drug Delivery Technologies
San Diego, California--(Newsfile Corp. - May 10, 2022) - Mycrodose Therapeutics showed the ability to synthesize and stabilize psilocin in their laboratory for use in their IP-protected drug delivery systems. The company successfully delivered in vitro both macro and microdose levels of psilocin through human skin using their patch and lozenge technologies. Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company specializing in the development of advanced drug delivery (ADD)...
2022-05-10 8:47 AM EDT
Mycrodose Therapeutics Announces First Clinical Candidate for Ketamine-Based Drug Delivery Device for Oral Mucositis
San Diego, California--(Newsfile Corp. - March 31, 2022) - Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company specializing in the development of advanced drug delivery technologies utilizing DEA Schedule I & III drugs and other compounds, announced today their lead clinical drug delivery system with a ketamine-based treatment for oral mucositis associated with cancer patients undergoing chemotherapy and radiation therapy. Mycrodose's first clinical candidate, MDT-001,...
2022-03-31 4:32 PM EDT
Mycrodose Therapeutics Granted DEA and FDA Approval to Cultivate Psilocybin Mushrooms in the United States
San Diego, California--(Newsfile Corp. - February 23, 2022) - Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company specializing in the development of advanced drug delivery systems to treat cancer related conditions, mental health, and cognitive degenerative diseases, announced today the US Drug Enforcement Agency (DEA) and the US Food and Drug Administration (FDA) have approved the company to cultivate Psilocybe cubensis and synthesize five (5) Schedule I compounds under...
2022-02-23 7:55 AM EST
Mycrodose Therapeutics Expands Scientific Advisory Board with the Addition of Dr. Yavorsky and Dr. Jacques
San Diego, California--(Newsfile Corp. - December 14, 2021) - Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company developing advanced drug delivery technologies for use with psychedelic compounds, is pleased to announce the appointment of Dr. Christian Yavorsky and Dr. Jacqueline Jacques to its Scientific Advisory Board. Dr. Yavorsky is a psychologist by training and has worked in clinical trials in the pharmaceutical industry for nearly twenty years. He has worked...
2021-12-14 5:05 AM EST
Mycrodose Therapeutics Successfully Completes Oversubscribed Private Placement to Expand Existing Patent Portfolio of Breakthrough Advanced Drug Delivery Technologies
Mycrodose Therapeutics successfully closes oversubscribed seven-figure financing round.Financing was funded by multiple high profile institutional investors, VCs, and Psychedelic Funds, including; The Conscious Fund, Negev Capital, Ambria Capital, K2 & Associates, Empath Ventures, Supernode, Receptor Fund, and many high profiles Silicon Valley Executives. Mycrodose Therapeutics is widely recognized as the first company to bring Advanced Drug Delivery Technologies (ADD) into the Psychedelic...
2021-09-21 5:55 AM EDT
Mycrodose Therapeutics Announces Expansion of Southern California Pharmaceutical Laboratory
San Diego, California--(Newsfile Corp. - September 2, 2021) - Mycrodose Therapeutics, a US pharmaceutical company focused on developing advanced drug delivery systems for use with psychedelic compounds, announced today the expansion of their Southern California Pharmaceutical laboratory. Earlier this year, Mycrodose Therapeutics was approved by the United States Drug Enforcement Agency (DEA), State of California Attorney General's Research Advisory Board, and The US Food & Drug Administration...
2021-09-02 6:55 AM EDT